Head to Head Survey: InspireMD (NSPR) vs. Its Competitors
by Kim Johansen · The Markets DailyInspireMD (NYSE:NSPR – Get Free Report) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its rivals? We will compare InspireMD to related companies based on the strength of its dividends, analyst recommendations, profitability, valuation, risk, institutional ownership and earnings.
Analyst Recommendations
This is a breakdown of current ratings and price targets for InspireMD and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| InspireMD | 0 | 0 | 3 | 0 | 3.00 |
| InspireMD Competitors | 4257 | 10483 | 18210 | 824 | 2.46 |
InspireMD presently has a consensus target price of $4.50, indicating a potential upside of 900.00%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 25.77%. Given InspireMD’s stronger consensus rating and higher possible upside, analysts clearly believe InspireMD is more favorable than its rivals.
Earnings & Valuation
This table compares InspireMD and its rivals gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| InspireMD | $10.84 million | -$19.92 million | -0.70 |
| InspireMD Competitors | $1.89 billion | $138.79 million | 10.75 |
InspireMD’s rivals have higher revenue and earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
44.8% of InspireMD shares are held by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 25.0% of InspireMD shares are held by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility and Risk
InspireMD has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, InspireMD’s rivals have a beta of 2.57, meaning that their average stock price is 157% more volatile than the S&P 500.
Profitability
This table compares InspireMD and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| InspireMD | -413.96% | -69.42% | -57.68% |
| InspireMD Competitors | -278.23% | -150.06% | -21.87% |
Summary
InspireMD rivals beat InspireMD on 7 of the 13 factors compared.
InspireMD Company Profile
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.